Quick Answer
Foghorn Therapeutics Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
Foghorn Therapeutics Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2021 | $0.00 | -100.0% |
| 2020 | $19.65M | +79.3% |
| 2019 | $10.96M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2021 | $19.91M | +126.3% | +0.4% |
| June 30, 2021 | $19.83M | — | +0.4% |
| March 31, 2021 | $19.74M | — | +0.4% |
| December 31, 2020 | $19.65M | +79.3% | +123.3% |
| September 30, 2020 | $8.80M | — | -19.7% |
| December 31, 2019 | $10.96M | — | — |
- Foghorn Therapeutics Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2021 period, Foghorn Therapeutics Inc.’s long-term debt has declined by 100.0% (from $10.96 million to $0.00).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 10, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: